Clinical trials
Completed Phase 2 Epilepsy trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
113 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 7 |
| 2003 | 3 |
| 2004 | 5 |
| 2005 | 10 |
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 9 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 8 |
| 2017 | 5 |
| 2018 | 13 |
| 2019 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 113 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UCB Pharma | 12 |
| Jazz Pharmaceuticals | 9 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 7 |
| Eisai Co., Ltd. | 5 |
| Marinus Pharmaceuticals | 5 |
| Bial - Portela C S.A. | 4 |
| Eisai Inc. | 4 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 4 |
| UCB BIOSCIENCES, Inc. | 4 |
| SK Life Science, Inc. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Epilepsy | 113 |
| Seizures | 44 |
| Epilepsies, Partial | 13 |
| Brain Diseases | 7 |
| Migraine Disorders | 4 |
| Autistic Disorder | 3 |
| Epilepsies, Myoclonic | 3 |
| Tuberous Sclerosis | 3 |
| Brain Injuries, Traumatic | 2 |
| Central Nervous System Diseases | 2 |
Trials
Showing 1 to 25 of 113. Each trial links to its page on Pharma Observatory.
13 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.